The journey from vascular biology to the clinic: reducing inflammation lowers CV risk
Inflammation expert opinionsAug. 28, 2017
Video navigation menu
- CV event reduction as a consequence of lowering inflammation: top-line results of the CANTOS-trial 0:38
- The beginning of vascular biology research on the inflammation hypothesis 1:10
- Translation of experimental research into clinical application 3:10
- What are the potential adverse effects of inhibiting IL-1β and how might they be mitigated? 5:15
- 'Adverse events' in the CANTOS trial also include favorable side-effects 6:19
- Considering the CANTOS results, where should we go from here? 7:15
The CANTOS trial is the first in a series of trials that test the hypothesis that inhibiting inflammation can lower residual CV risk. The results of this trial indeed confirm this hypothesis, suggesting that from now on, targeting inflammation may need to be considered in patients on lipid-lowering therapy with residual inflammatory CV risk.
These inflammation expert opinion videos are aimed to provide guidance and perspectives on the implications of the CANTOS trial and other trials addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.
Prof. Paul Ridker - is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital. A cardiovascular medicine specialist, and Eugene Braunwald Professor of Medicine at Harvard School of Medicine.
Prof. Peter Libby - is Mallinckrodt Professor of Medicine, Harvard Medical School; Senior Physician, Brigham and Women's Hospital, Boston, MA, USA
Funding to produce this video was provided by an unrestricted educational grant from Novartis.